The Top 3 Preclinical Considerations in the Discovery and Development of Novel Oncology TherapeuticsHosted By : Andrea Charles
November 6, 2012
About this Podcast...
In this interview Kenneth J. Olivier Jr., PhD, Director of Toxicology at Merrimack Pharmaceuticals, speaks to Andrea Charles from Pharma IQ, about what trends he is witnessing in the improvement of safety assessments, his top 3 preclinical considerations in the discovery and development of novel oncology therapeutics and the implications and future considerations for use of computational biology in clinical drug development.
Have Your Say
Rate this feature and give us your feedback in the comments section below
Exploring Challenges and Opportunities in Predictive Safety Tools: Trends from Industry-Wide Surveys
January 13, 2012
Taking EDC to the next level: Moving from point solutions to an eClinical ecosystem
April 4, 2013
EU Product Launch – Key Considerations for Successful Niche and Orphan Drug Product Launches
February 9, 2012